Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says
Portfolio Pulse from Vandana Singh
William Blair has initiated coverage on AbbVie Inc with a Market Perform rating. The analysts noted that while AbbVie was prepared for the launch of Humira biosimilars, the loss of exclusivity is complicated by growing competition in the hematology and aesthetic franchises. The launch of Beigene Limited's Brukinsa intensifies competitive pressure. AbbVie's shares are expected to trade roughly in line with the market as Humira pricing and volume erode over the next 12 months.
July 25, 2023 | 7:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The launch of Beigene's Brukinsa intensifies competition in the hematology franchise.
The launch of Beigene's Brukinsa, which has shown superiority in head-to-head studies, could positively impact its stock performance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
AbbVie faces growing competition in the hematology and aesthetic franchises, which could impact its stock performance.
The loss of exclusivity for Humira and the launch of Beigene's Brukinsa are increasing competition for AbbVie, which could negatively impact its stock performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100